{"brief_title": "Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation", "brief_summary": "This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.", "condition": ["Hepatitis B"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Entecavir (ETV)", "Adefovir (ADV)"], "description": ["Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized", "Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized"], "arm_group_label": ["A1", "A2"], "other_name": ["Baraclude", "BMS-200475"], "criteria": "Inclusion - Child-Pugh (CP) score >= 7 - Hepatitis B virus (HBV) viremia Exclusion - Alanine aminotransferase (ALT) > 15 x upper limit of normal (ULN) - Human immunodeficiency virus (HIV)/hepatitis C virus (HCV)/hepatitis D virus (HDV) coinfection", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "hepatic decompensation", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis B", "Liver Failure", "Adefovir", "Adefovir dipivoxil", "Entecavir"], "id": "NCT00065507"}